In this article, we reviewed the literature on risk assessment (RA) models with and without molecular genomic markers and the current utility of the markers in the pharmacogenetic field. Epidemiological risk assessment is applied using statistical models and equations established from current scientific knowledge of risk and disease. Several papers have reported that traditional RA tools have significant limitations in decision-making in management strategies for individuals as predictions of diseases and disease progression are inaccurate. Recently, the model added information on the genetic susceptibility factors that are expected to be most responsible for differences in individual risk. On the continuum of health care, from diagnosis to treatment, pharmacogenetics has been developed based on the accumulated knowledge of human genomic variation involving drug distribution and metabolism and the target of action, which has the potential to facilitate personalized medicine that can avoid therapeutic failure and serious side effects. There are many challenges for the applicability of genomic information in a clinical setting. Current uses of genetic markers for managing drug therapy and issues in the development of a valid biomarker in pharmacogenetics are discussed.
INTRODUCTION
There is a growing interest in the epidemiologic research field of genomic molecular based health care for early detection of illness and individual therapy. Many common and complex diseases are generally considered to be a multifactorial disorders; understanding genetic and molecular data and the related multifactorial etiological factors is essential for risk assessment. The goal of the molecular and genomic epidemiologic field is to understand the effects of various exposures on disease outcome and the genetic variability that may alter the prevention and treatment of disease. Molecular genomic markers can play a role in more accurately predicting disease development, drug response, and dosage optimization of drugs by adding markers to previous risk assessment tools. This has implications for personalized predictive prevention of disease development and progression, personalized treatment of diseases, and drug discovery and development. In this article, we reviewed the literature related to risk assessment models with and without molecular genomic markers and the current utility of the markers in the pharmacogenetic area.
RISK ASSESSMENT IN MOLECULAR AND GENOMIC EPIDEMIOLOGY
Risk assessment (RA), a step in the risk management process in environmental and occupational health, estimates the probability of a hazard effect of risk factors in individuals or populations. Environmental and occupational health focuses on chemicals and toxic materials above a certain threshold that are risk factors for various diseases and death. In environmental and occupational health, the risk assessment process includes Hazard Identification , a Dose-response Assess-ment between the exposure dose and probability or incidence of effect, and Exposure Quantification for the determina-tion of the dosage that people receive [1] .
In epidemiology, risk assessment estimates the chances of developing a disease over a specified interval in a person with certain risk factors. Epidemiological risk assessment is applied using statistical models and equations established from current scientific knowledge pertaining to etiology and the risk factors of disease. The RA models used in epidemiology are classified into four types according to the aim, study design of the baseline data, statistical model construction, and target population. These are summarized in Table 1 .
The first is the absolute risk model. In this model, a cohort study with sufficient follow-up was used to compute the real probability of disease development in a cohort with sufficient follow-up periods. This model computes the probability of a person s risk using Cox s proportional hazard model. The disease
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The second model uses a competing risk analysis. It is based on data from a case-control study design for relative risk (RR) estimates and general population statistics as incidence and mortality rates. Disease probability in the future is calculated using integral calculus equations based on age-specific data such as joint odds ratios calculated by a combination of risk factors in case-control studies and the incidence rates of a certain disease along with the mortality rates of other diseases. The target population is the general population. Many RA models use the competing risk method. A wellknown example is The Breast Cancer Risk Assessment Tool (BCRAT) designed by the National Cancer Institute and the National Surgical Adjuvant Breast and Bowel Project that aimed to estimate a woman s risk of developing invasive breast cancer from 1989 [4] . The initial model was intended for Caucasian women but has been updated for African-American women using the Contraceptive and Reproductive Experiences study [20] .
The third type is the relative risk model of the Harvard Cancer Risk Index reported in 2000 [11] . The Risk Index Working Group at Harvard University used group consensus among researchers to classify risk factors into definite, probable, and possible causes of cancer. Baseline information was collected from representative studies and a risk score was developed through researchers consensus. The relative risks due to individual risk factors from the representative data were converted to cancer risk points according to the strength of the causal association. The risk estimates were then totaled. The total was divided by the population average risk of cancer for a person with the same age and sex and multiplied by the average 10-year risk for disease from the Surveillance, Epidemiology and End Results (SEER) data that calculated the 10-year cumulative risk in the US population [11] .
The fourth model is targeted to specific populations such as specific heredity factors or families. An example is the BACAPRO model for breast cancer risk prediction due to BRCA 1/2 gene mutations and a family history of breast and ovarian cancer [12] .
Although several risk prediction models exist at present, accurately predicting an individual s risk for disease remains a challenge. Several papers have reported that traditional RA tools do not accurately predict coronary heart disease [21] . Substantial limitations have also been reported when these tools are used to guide individual therapy [22, 23] . There are significant limitations in breast cancer models, such as their ability to predict breast cancer risk accurately when allowing for individualization of management strategies as well as model limits in ensuring that appropriate and autonomous decision-making takes place [24] .
Advances in information pertaining to genetic susceptibility factors are expected to be most responsible for the differences in individual disease risk. It is anticipated that revised RA risk models which incorporate gene information and molecular markers will improve prediction accuracy. Dr. Mitchell H. Gail at the US National Cancer Institute added seven single-nucleotide polymorphisms (SNPs) that had previously been associated with breast cancer to the BCRAT. Although the model that included the SNPs provided less discriminatory accuracy than the BCRAT, it showed the potential to improve the discriminatory accuracy of the BCRAT modestly (the area under the receiver operating characteristic curve from 0.607 to 0.632) [25] . Dr. Gail showed small improvements in the Aim: to estimate the probability of disease development Target population: specific population with heredity or family history of a certain disease Baseline data and study design: family history in the specific populations based on pedigrees and/or prevalence of gene mutation Statistical method: Penetrance estimation and disease developing risk calculation according to gene mutation Aim: to estimate the conditional probability given a certain disease Target population: general population or specific population exposed to specific factors such as toxicants Baseline data and study design: case-control (diagnosis, high risk group detection) or case series data (prognosis) Statistical method: logistic regression model Framingham heart score [2, 3] BARAT [4] Colon cancer [5, 6] Lung cancer [7, 8] Prostate cancer [9] Melanoma [10] Harvard Cancer Risk Index [11] With genetic information: BRCAPRO [12] PancPRO [13] Without genetic information: Claus model [14] IBIS (Tyrer-Cuzick) model [15] Clinicogenomic model for lung cancer diagnosis [16] Model for silica exposed population [17] Model for occupational asthma [18] uncertainty to assume equal weight for each allele and the arbitrary assignment of the unfavorable allele in a case in which no information pertaining to functional inferiority [38] . In contrast, the genome-wide scanning approach is a hypothesis-generating design that does not depend on current knowledge to conduct a non-biased global genome assessment. Although the modest effect size of common variants, even in combination, leads to an argument of biological plausibility [39, 40] , the GWAS approach expects to discover the biologic pathways in polygenic traits [41] . Through the progress of human genetic variation and the haplotype map (known as the HapMap) coupled with rapid improvements in genotyping technology and analysis, 416 genome-wide association studies (GWAS) attempted to assay at least 100,000 SNPs in the first stage, and SNP-trait associations with p-values of less than 1.0 x 10
have been published thus far, reporting 400 novel GWAS loci in 75 diseases in a catalog published by the Human Genome Research Institute [42] . However, it appears premature to launch a GWAS in PGx because drug response as an outcome is more complex and the sample size with specific types of responder/nonresponder or adverse reactions is much smaller compared to a typical disease-association study. Therefore, tremendous international collaboration is required in terms of a treatment regimen and drug response, such as that for SLCO1B1 and statin-induced myopathy, as conducted in two sets of patient and control groups from large trials of approximately 12,000 and 20,000 participants from the SEARCH Collaborative Group [43] . In the guidance for industry pharmacogenomic data submissions issued by the US FDA, a valid genomic biomarker is defined as a biomarker that is measured in an analytical test system with well-established performance characteristics and for which there is an established scientific framework or body of evidence that elucidates the physiologic, toxicologic, pharmacologic, or clinical absorption, disposition, and effect (efficacy and safety) [28] . Given that researchers reported an inherited basis for drug-response phenotypes in enzyme activity studies in the 1950s (reviewed in [29] ), pharmacogenetic biomarkers have the potential to identify responders and nonresponders, avoid toxicity and adjust the dosage of drugs to optimize efficacy and safety for each patient by providing an integrated approach to developments in genomics and associated technological innovations. This has implications not only for individual treatment but for drug discovery and development methods [30] .
Early PGx studies were hypothesis-based candidate gene approaches that resulted in a few striking examples, such as 6-mercapto purine and TPMT [31] , clopidogrel and CYP2C19 [32] , irinotecan and UGT1A1 [33] and carbamazepine and the HLA-B*1502 allele [34] . The simple methodology and statistical analysis used in conjunction with a comparably small sample size is the advantage of the candidate approach; however, it is rare to find strong and monogenic polymorphism candidates for drug response, low power for polygenic traits, and limited knowledge of gene and polymorphic function and drug pathways [35] , thereby missing the true candidate gene and variation. As an extension of the candidate gene approach, a pathway-based genotype approach evaluates the combined effects of multiple genes in the same and/or different pathways to identify more sensitive and specific predictor profiles of drug response, such as CYP2C9 as a metabolizing enzyme and VKORC1 as a drug target for warfarin dosing [36] , and DNA repair genes (XPD, ERCC1, and XRCC1) for clinical outcome of cisplatin-based chemotherapy [37] to amplify the modest effects of individual polymorphisms and enhance the predictive power. However, this remains limited by previous knowledge in its selection of the genes and pathways for drugs. It is often difficult to analyze the gene-gene interaction based on the a priori biological pathway due to the benefit when deciding whether to take tamoxifen for prevention and whether to recommend mammogram screening in the BCRAT plus 7 SNPs model compared with the BCRAT [26] . New RA models with genetic information will effectively characterize substantial high-risk individuals in populations exposed to silica [17] and occupational asthmatic factors [18] . Moreover, experience in molecular genetic testing applied to patients prognosis and diagnosis provides knowledge that molecular genomic markers play an important role in the pre-detection and prognosis of individual diseases in a variety of clinical contexts, which heralds the future of genomics-based Personalized Predictive Preventive Medicine as idealized by Dr. Francis Collins. Two examples are as follows. MammaPrint is a molecular genomic diagnostic test that assesses the risk of breast cancer progression and drug response. It is more accurate in predicting a patient s prognosis relative to clinicopathological factors such as the tumor size and lymphatic invasion [27] . The second example is a combined clinicgenomic model that adds gene expression markers to traditional clinical factors for lung cancer diagnosis. It can diagnose lung cancer with higher validity (nearly 100% sensitivity and 91% specificity), even when the physician s diagnosis is uncertain [16] . We expect improvements in the power of elucidation on human risk assessment by adding molecular genomic factors. These new RA models, which include molecular genomic markers, will increase predictability by reducing misclassification bias through more valid exposure biomarkers.
PHARMACOGENOMICS IN MOLECULAR AND GENOMIC EPIDEMIOLOGY
Pharmacogenetics or pharmacogenomics (PGx) is the study of variations in DNA and RNA related to drug response, including drug significance of the test results [44] . There have been a limited number of potentially useful examples of pharmacogenomic DNA and RNA variant biomarkers approved by the FDA, although they are categorized as test recommended or information only (Table 2) .
To overcome the challenges related to the applicability of genomic information as a valid biomarker in clinical practice, the study design needs to be considered. Most studies published were based on observational retrospective assessments of patients receiving treatment while the heterogeneity of the disease and treatment increased the likelihood of spurious findings. Although in the context of experimental designs (clinical trials), valid retrospective studies of a genomic biomarker require data from well-conducted randomized clinical trials; sample availability on a majority of patients to avoid selection bias; a prospectively stated hypothesis, analysis techniques, predefined and standardized assay and scoring system; and large sample size and power justification (reviewed in [45] ). The gold standard is the prospective clinical trials that provide the setting for the evaluation of genomic biomarker validation, although this method is in general more expensive than an observational study. For example, the Trial Assigning Individualized Options for Treatment (TAILORx) was designed to integrate the 21-gene assay into the clinical decision-making process based on genomic biomarker recurrence scores in tamoxifentreated patients with breast cancer [46] . Table 3 summarizes the general pros and cons of various study approaches.
Other issues as we move toward clinical integration of PGx information include the following: 1) defining drug response, suitably defined clinical endpoints (i.e., death), biomarkers or surrogate endpoints; 2) careful and sophisticated analysis of inter-individual variability in the demographic, environmental, lifestyle, and/or physiologic factors that affect drug response; 3) a cut off value for biomarkers based on supportive and rational analytical data and on the study design; 4) ethnic differences and population stratification; 5) the use of comprehensive inherited information such as epigenetic factors and copy number variation as well as genetic factors to improve sensitivity.
SUMMARY
Risk assessment and personalized medicine using molecular and genomic markers is a young field that holds considerable promise for contributions to healthcare by prevention, Slow acetylation may lead to higher blood levels of the drug Thiopurine methyltransferase deficiency or lower activity due to mutation increased exposure to drug Nilotinib UGT1A1 mutation with decreased expression is associated with higher systemic exposure to drugs earlier diagnosis, early intervention, effective interventions, and better outcomes. The major challenges associated with genetic biomarkers appear to be a lack of reproducibility and validation. Collaborative effort from various experts such as epidemiologists, clinicians, biologists, and biostatisticians is needed for further development and for the creation of novel approaches.
